Evidence map›Paper›PMID 23300970›Full record

ArticlePloS one2013

Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies.

Patrycja J Lech, Gregory J Tobin, Ruth Bushnell, Emily Gutschenritter, Linh D Pham, Rebecca Nace, Els Verhoeyen, François-Loïc Cosset, Claude P Muller, Stephen J Russell and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Glycoproteins in Viruses.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  2. Article
  3. Measles Resurgence and Drug Development.Current opinion in virology · 2020
    Review
  4. Review
  5. Measles, the need for a paradigm shift.European journal of epidemiology · 2019
    Review
  6. Review
  7. Oncolytic viruses: overcoming translational challenges.The Journal of clinical investigation · 2019
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Patrycja J LechDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America. Lech.patrycja@mayo.edu
Gregory J Tobin
Ruth Bushnell
Emily Gutschenritter
Linh D Pham
Rebecca Nace
Els Verhoeyen
François-Loïc Cosset
Claude P Muller
Stephen J Russell
Peter L Nara
Biological Mimetics (United States) · USMayo Clinic · USÉcole Normale Supérieure de Lyon · FRInserm · FRLaboratoire National de Santé · LUMayo Clinic in Arizona · USWinnMed · US

Funding

Antibody Neutralization of Therapeutic VirusesR01CA129966 · NCI · MAYO CLINIC ROCHESTER · PI RUSSELL, STEPHEN J · 2008 to 2012
$2.5M
NCI NIH HHS R01 CA129966
6 · The paper itself

Abstract

The measles virus (MV) is serologically monotypic. Life-long immunity is conferred by a single attack of measles or following vaccination with the MV vaccine. This is contrary to viruses such as influenza, which readily develop resistance to the immune system and recur. A better understanding of factors that restrain MV to one serotype may allow us to predict if MV will remain monotypic in the future and influence the design of novel MV vaccines and therapeutics. MV hemagglutinin (H) glycoprotein, binds to cellular receptors and subsequently triggers the fusion (F) glycoprotein to fuse the virus into the cell. H is also the major target for neutralizing antibodies. To explore if MV remains monotypic due to a lack of plasticity of the H glycoprotein, we used the technology of Immune Dampening to generate viruses with rationally designed N-linked glycosylation sites and mutations in different epitopes and screened for viruses that escaped monoclonal antibodies (mAbs). We then combined rationally designed mutations with naturally selected mutations to generate a virus resistant to a cocktail of neutralizing mAbs targeting four different epitopes simultaneously. Two epitopes were protected by engineered N-linked glycosylations and two epitopes acquired escape mutations via two consecutive rounds of artificial selection in the presence of mAbs. Three of these epitopes were targeted by mAbs known to interfere with receptor binding. Results demonstrate that, within the epitopes analyzed, H can tolerate mutations in different residues and additional N-linked glycosylations to escape mAbs. Understanding the degree of change that H can tolerate is important as we follow its evolution in a host whose immunity is vaccine induced by genotype A strains instead of multiple genetically distinct wild-type MVs.

Indexed as

MutationAdenoviridaeAnimalsAntibodies, MonoclonalAntibodies, NeutralizingChlorocebus aethiopsCHO CellsCricetinaeEpitopesGlycosylationHemagglutinins, ViralHumansMeasles VaccineMeasles virusMiceMice, Inbred BALB CAntibodies, MonoclonalAntibodies, NeutralizingEpitopeshemagglutinin protein G, measles virusHemagglutinins, ViralMeasles VaccineRecombinant Proteins

Identifiers

PMID23300970
PMCPMC3536790
OpenAlexW2077451586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.